List of Proteostasis Therapeutics patents

List of Proteostasis Therapeutics patents

List of University of Tartu patents

List of Narus Inc patents

List of Polaris Wireless patents

List of companies in Disruptive Technologies Innovation Fund's investment portfolio

Investors in HCVC

Patents where

Current Assignee

Name

is

Proteostasis Therapeutics

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 10017503 Compounds, compositions, and methods for increasing CFTR activity	Patent 10017503 was granted and assigned to Proteostasis Therapeutics on July, 2018 by the United States Patent and Trademark Office.	‌ Proteostasis Therapeutics, Inc.	Proteostasis Therapeutics		United States Patent and Trademark Office	10017503	July 10, 2018
	‌ US Patent 11560385 Proteasome activity enhancing compounds		Proteostasis Therapeutics	Proteostasis Therapeutics		United States Patent and Trademark Office	11560385	January 24, 2023
	‌ US Patent 11242361 Proteasome activity enhancing compounds	Patent 11242361 was granted and assigned to Proteostasis Therapeutics on February, 2022 by the United States Patent and Trademark Office.	Proteostasis Therapeutics	Proteostasis Therapeutics		United States Patent and Trademark Office	11242361	February 8, 2022
	‌ US Patent 10899751 Compounds, compositions, and methods for increasing CFTR activity	Patent 10899751 was granted and assigned to Proteostasis Therapeutics on January, 2021 by the United States Patent and Trademark Office.	Proteostasis Therapeutics	Proteostasis Therapeutics		United States Patent and Trademark Office	10899751	January 26, 2021
	‌ US Patent 11248010 Compounds, compositions, and methods for modulating CFTR	Patent 11248010 was granted and assigned to Proteostasis Therapeutics on February, 2022 by the United States Patent and Trademark Office.	Proteostasis Therapeutics	Proteostasis Therapeutics		United States Patent and Trademark Office	11248010	February 15, 2022
	‌ US Patent 10662207 Compounds, compositions, and methods for modulating CFTR	Patent 10662207 was granted and assigned to Proteostasis Therapeutics on May, 2020 by the United States Patent and Trademark Office.	Proteostasis Therapeutics	Proteostasis Therapeutics		United States Patent and Trademark Office	10662207	May 26, 2020
	‌ US Patent 10550106 Compounds, compositions, and methods for modulating CFTR	Patent 10550106 was granted and assigned to Proteostasis Therapeutics on February, 2020 by the United States Patent and Trademark Office.	‌ Proteostasis Therapeutics, Inc.	Proteostasis Therapeutics		United States Patent and Trademark Office	10550106	February 4, 2020
	‌ US Patent 10548878 Compounds, compositions, and methods of increasing CFTR activity	Patent 10548878 was granted and assigned to Proteostasis Therapeutics on February, 2020 by the United States Patent and Trademark Office.	‌ Proteostasis Therapeutics, Inc.	Proteostasis Therapeutics		United States Patent and Trademark Office	10548878	February 4, 2020
	‌ US Patent 10344023 Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis	Patent 10344023 was granted and assigned to Proteostasis Therapeutics on July, 2019 by the United States Patent and Trademark Office.	‌ Proteostasis Therapeutics, Inc.	Proteostasis Therapeutics		United States Patent and Trademark Office	10344023	July 9, 2019
	‌ US Patent 10174014 Compounds, compositions, and methods for increasing CFTR activity	Patent 10174014 was granted and assigned to Proteostasis Therapeutics on January, 2019 by the United States Patent and Trademark Office.	‌ Proteostasis Therapeutics, Inc.	Proteostasis Therapeutics		United States Patent and Trademark Office	10174014	January 8, 2019
	‌ US Patent 10392378 Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis	Patent 10392378 was granted and assigned to Proteostasis Therapeutics on August, 2019 by the United States Patent and Trademark Office.	‌ Proteostasis Therapeutics, Inc.	Proteostasis Therapeutics		United States Patent and Trademark Office	10392378	August 27, 2019
	‌ US Patent 10392372 Compounds, compositions, and methods for increasing CFTR activity	Patent 10392372 was granted and assigned to Proteostasis Therapeutics on August, 2019 by the United States Patent and Trademark Office.	‌ Proteostasis Therapeutics, Inc.	Proteostasis Therapeutics		United States Patent and Trademark Office	10392372	August 27, 2019
	‌ US Patent 10738040 Compounds, compositions, and methods for increasing CFTR activity		Proteostasis Therapeutics	Proteostasis Therapeutics		United States Patent and Trademark Office	10738040	August 11, 2020
	‌ US Patent 10738011 Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis		‌ Proteostasis Therapeutics, Inc.	Proteostasis Therapeutics		United States Patent and Trademark Office	10738011	August 11, 2020
	‌ US Patent 11136313 Compounds, compositions, and methods for modulating CFTR	Patent 11136313 was granted and assigned to Proteostasis Therapeutics on October, 2021 by the United States Patent and Trademark Office.	Proteostasis Therapeutics	Proteostasis Therapeutics		United States Patent and Trademark Office	11136313	October 5, 2021
	‌ US Patent 11083709 Compounds, compositions, and methods of increasing CFTR activity	Patent 11083709 was granted and assigned to Proteostasis Therapeutics on August, 2021 by the United States Patent and Trademark Office.	Proteostasis Therapeutics	Proteostasis Therapeutics		United States Patent and Trademark Office	11083709	August 10, 2021
	‌ US Patent 11098035 Compounds, compositions, and methods for increasing CFTR activity	Patent 11098035 was granted and assigned to Proteostasis Therapeutics on August, 2021 by the United States Patent and Trademark Office.	Proteostasis Therapeutics	Proteostasis Therapeutics		United States Patent and Trademark Office	11098035	August 24, 2021
	‌ US Patent 11746098 Proteasome activity enhancing compounds	Patent 11746098 was granted and assigned to Proteostasis Therapeutics on September, 2023 by the United States Patent and Trademark Office.	Proteostasis Therapeutics	Proteostasis Therapeutics		United States Patent and Trademark Office	11746098	September 5, 2023

18 results

0 selected

18 results

0 selected